N/A
N=147
Trial of Rifaximin in the Treatment of Tropical Enteropathy
Tropical Enteropathy
Bottom Line
View on ClinicalTrials.gov: NCT00858988 ↗Enrolled (actual)
147
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Rifaximin (Drug); Placebo (Drug)
- Age
- Pediatric · 3+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Oct 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference in the Urinary L:M Ratio Before and After the Intervention |
-0.01; 0.02 | — |
Summary
The purpose of this study is to determine whether rifaximin is effective in the treatment of tropical enteropathy in a population of African children at high risk for this disease.
Eligibility Criteria
Inclusion Criteria
- live in single village
Exclusion Criteria
- acutely malnourished
- acutely ill
- chronic disease
Data sourced from ClinicalTrials.gov (NCT00858988). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.